CCR5 antagonists in the treatment of HIV-infected persons: is their cancer risk increased, decreased, or unchanged.
McNiff
Todd
T
Pfizer, Inc, New York, USA.
Dezube
Bruce J
BJ
D019380:Anti-HIV Agents / Q000009:adverse effects*; D065100:CCR5 Receptor Antagonists; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D009369:Neoplasms / Q000139:chemically induced* / Q000145:classification; D010879:Piperazines / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D019713:Receptors, CCR5 / Q000235:genetics; D016896:Treatment Outcome
D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D010879:Piperazines; D011743:Pyrimidines; D019713:Receptors, CCR5; C486781:vicriviroc